个性化医疗
癌症
医学
药物发现
精密医学
胃肠道癌
药品
类有机物
药物开发
重症监护医学
生物信息学
内科学
药理学
结直肠癌
病理
生物
神经科学
作者
Zhenjie Yang,Jun Yu,Sunny H. Wong
出处
期刊:Cells
[MDPI AG]
日期:2024-08-06
卷期号:13 (16): 1312-1312
标识
DOI:10.3390/cells13161312
摘要
Cancer is a leading cause of death worldwide. Around one-third of the total global cancer incidence and mortality are related to gastrointestinal (GI) cancers. Over the past few years, rapid developments have been made in patient-derived organoid (PDO) models for gastrointestinal cancers. By closely mimicking the molecular properties of their parent tumors in vitro, PDOs have emerged as powerful tools in personalized medicine and drug discovery. Here, we review the current literature on the application of PDOs of common gastrointestinal cancers in the optimization of drug treatment strategies in the clinic and their rising importance in pre-clinical drug development. We discuss the advantages and limitations of gastrointestinal cancer PDOs and outline the microfluidics-based strategies that improve the throughput of PDO models in order to extract the maximal benefits in the personalized medicine and drug discovery process.
科研通智能强力驱动
Strongly Powered by AbleSci AI